Enter to win every day in CTNOW's 21 Days of Summer Giveaways. Click here to see today's prize.
Topics

Cystic Fibrosis

FDA clears drug for leading form of cystic fibrosis

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will come at a steep price — more than $250,000 for a year's treatment. The Food and Drug Administration cleared the twice-a-day pill from Vertex Pharmaceuticals Inc. for a variation of cystic fibrosis that affects about 8,500 people in the U.S. who are 12 years and older. The approval notice was posted to the agency's website Thursday. The new drug — to be sold as Orkambi — is Vertex's follow-up to its breakthrough pill Kalydeco, which became...

Loading
74°